[Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)]

Internist (Berl). 2008 Apr;49(4):502-4. doi: 10.1007/s00108-008-2067-2.

[Article in German]

Authors

J D Ringe¹, S Nitschmann

Affiliation

¹ Westdeutsches Osteoporose Zentrum, Medizinische Klinik 4, Klinikum Leverkusen, 51375, Leverkusen, Germany. ringe@klinikum-lev.de

PMID: 18305914
DOI: 10.1007/s00108-008-2067-2

No abstract available

MeSH terms

Aged
Bone Density / drug effects
Bone Density Conservation Agents / administration & dosage*
Bone Density Conservation Agents / adverse effects
Diphosphonates / administration & dosage*
Diphosphonates / adverse effects
Drug Administration Schedule
Female
Fractures, Spontaneous / prevention & control*
Humans
Imidazoles / administration & dosage*
Imidazoles / adverse effects
Infusions, Intravenous
Male
Osteoporosis / drug therapy*
Randomized Controlled Trials as Topic
Secondary Prevention
Zoledronic Acid

Substances

Bone Density Conservation Agents
Diphosphonates
Imidazoles
Zoledronic Acid